Tapering is best reserved for those in complete remission with stable disease for at least 6 months, although many individual patient characteristics must be taken into account, experts say.
Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target trial emulation.
In the study, patients exposed to Dry Hydrogen Peroxide (DHP™) had 61.4% lower odds of developing a hospital-acquired infection compared to patients who were not. - Click here if this is your press release! - eTurboNews | Trends | Travel News